title: Beyond ipilimumab: new approaches target the immunological synapse.
authors: Ken
authors: K
authors: Garber
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D015703:Antigens, CD / Q000187:drug effects / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D051017:Apoptosis Regulatory Proteins / Q000187:drug effects / Q000276:immunology; D019013:CD40 Antigens / Q000187:drug effects / Q000276:immunology; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval; D053450:Glucocorticoid-Induced TNFR-Related Protein / Q000187:drug effects / Q000276:immunology; D006801:Humans; D054992:Immunological Synapses / Q000187:drug effects*; D007167:Immunotherapy / Q000379:methods*; D000074324:Ipilimumab; D008213:Lymphocyte Activation / Q000187:drug effects; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology*; D000077594:Nivolumab; D053278:OX40 Ligand / Q000187:drug effects / Q000276:immunology; D061026:Programmed Cell Death 1 Receptor; D012878:Skin Neoplasms / Q000188:drug therapy / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000970:Antineoplastic Agents; D051017:Apoptosis Regulatory Proteins; D019013:CD40 Antigens; D053450:Glucocorticoid-Induced TNFR-Related Protein; D000074324:Ipilimumab; D053278:OX40 Ligand; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C491405:TNFRSF18 protein, human; C089251:TNFSF4 protein, human; D000077594:Nivolumab